Yuan Fei, Lerman Lilach O
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Department of Urology, National Children's Medical Center, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Expert Opin Ther Targets. 2024 Nov;28(11):979-989. doi: 10.1080/14728222.2024.2421756. Epub 2024 Nov 3.
Kidney diseases impose a significant burden with high incidence and mortality rates. Current treatment options for kidney diseases are limited, necessitating urgent development of novel and effective therapeutic strategies to delay or reverse disease progression. Targeted therapies for the kidney hold promise in significantly enhancing treatment outcomes, offering hope to patients afflicted with renal disorders.
This review summarized advances in kidney-targeted therapies including genes, peptides and proteins, cell-based, nanoparticles, and localized delivery routes. We also explored the potential clinical applications, prospects, and challenges of targeted therapies for renal disorders.
Advances in targeted therapies for renal conditions have enhanced therapeutic outcomes. Clinical application of kidney-targeted therapies is currently limited by renal structure and the scarcity of robust biomarkers. Bridging the gap from basic and pre-clinical research targeting the kidney to achieving clinical translation remains a formidable challenge.
肾脏疾病负担沉重，发病率和死亡率都很高。目前肾脏疾病的治疗选择有限，迫切需要开发新的有效治疗策略来延缓或逆转疾病进展。肾脏靶向治疗有望显著提高治疗效果，为患有肾脏疾病的患者带来希望。
本综述总结了肾脏靶向治疗的进展，包括基因、肽和蛋白质、基于细胞的、纳米颗粒以及局部递送途径。我们还探讨了肾脏疾病靶向治疗的潜在临床应用、前景和挑战。
肾脏疾病靶向治疗的进展提高了治疗效果。目前，肾脏靶向治疗的临床应用受到肾脏结构和可靠生物标志物稀缺的限制。从针对肾脏的基础和临床前研究到实现临床转化，缩小这一差距仍然是一项艰巨的挑战。
